Oncology Companion Diagnostics Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Size, Share & Trends, Drivers, Restraints, Opportunities, Manufacturer, Applications, And Segments

  • AMR-1064633
  • May 2021
  • Biotechnology
  • 140 Pages
The global Oncology Companion Diagnostics market research report provides complete study and detail analysis of the market. This study includes forecast analysis of the market which is based on global and regional level, whereas the research reports the provides forecast data from 2020-2028 and historic of 2018 and 2019. All the values are based on revenue USD Million. Moreover, the market research report describes various segments of the Oncology Companion Diagnostics market based on its types, applications and end-use industry. The applications of the market are explained in different industry verticals with reference to major countries across the globe. Along with this, the research report also covers all the major players that are operating in the global Oncology Companion Diagnostics market. These major players of the market are further studied and analyzed based on various parameters, such as annual market revenue, annual sales of the company, marketing strategy, historic growth and shipment volumes. Based on all the company’s insights, the market research analyst also suggests business strategy and marketing plans for improving the market position of existing participants of Oncology Companion Diagnostics market.
 
Report Parameters Details of Parameter
Market Size xx Million
Based Year 2020
Forecast Period Covered 2020 – 2028
Units for value Revenue in USD million and CAGR from 2020 to 2028
Covered Segments Component, Types, Applications, End-Users, and more.
Companies Covered Qiagen, Illumina, F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific, Inc, Agilent Technologies, Inc., Arup Laboratories, Abbott, Myriad Genetics, Inc, Biomérieux SA, Invivoscribe
Region Covered North America, Europe, Asia Pacific, Latin America, Middle East and Africa

COVID-19 Impact Analysis
The analysis of covid-19 is based on the impact of the current pandemic situation on market scenarios. This includes impact of covid-19 outbreak on overall revenue, market segments as well as regional market. The report also puts light on detailed impact analysis by taking into consideration all the government policies imposed during the pandemic situation, temporary shutdown of manufacturing units, current state of supply chain and distributors, and its future impacts on the growth of overall market. The market study will assist user to understand the global demand and impose strategic business plans to compete with the peers.

Apart from this, the market research report also covers drivers and restraints for the global Oncology Companion Diagnostics market and their impact on the demand and supply during the forecast period. Along with this, the research report also provides Oncology Companion Diagnostics market trends and opportunities that are based on regional and global level. Furthermore, the market research report also provides the major distributors and manufacturers that are operating in all the key region across the world. The researched data provided in the report is widely used by various industry players to strengthen their distribution channel and improve the geographical reach. In addition, the report also covers all the major players of the global Oncology Companion Diagnostics market and its key offerings and solutions. The report also provides recent mergers and acquisitions of these key players.

The data which is provided in the market research report is analyzed and evaluated with the help of various marketing tools, such as SWOT analysis, Poster’s Five Force analysis, PESTEL analysis, value chain analysis, player positioning analysis and market share analysis. Therefore, this analysis tools helps the analyst to evaluate the Oncology Companion Diagnostics market based on various parameters such as capital investments, impact of consumer’s preferences, economies of scale, manufacturing rights and patents, existing distribution channels, switching costs, government regulations and brand loyalty.

Major Key Players for Global Oncology Companion Diagnostics Market:
The Oncology Companion Diagnostics market research report offers the company profile of major key players including progress trends, competitive landscape breakdown, and key in regions development status. Qiagen, Illumina, F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific, Inc, Agilent Technologies, Inc., Arup Laboratories, Abbott, Myriad Genetics, Inc, Biomérieux SA, Invivoscribe

Oncology Companion Diagnostics Market Segment Analysis:
By Product
Instrument
Consumable
Software
Technology
Polymerase Chain Reaction
PCR
Next-Generation Sequencing
NGS
Immunohistochemistry
IHC
In Situ Hybridization
ISH/Fluorescence in Situ Hybridization
FISH
Other Technologies
Disease Type
Breast Cancer
Non-Small Cell Lung Cancer
Colorectal Cancer
Leukemia
Melanoma
Prostate Cancer
Others
End User
Hospital
Pathology/Diagnostic Laboratory
Academic Medical Center

Geographic Coverage for Oncology Companion Diagnostics Market:
The market research report on global Oncology Companion Diagnostics market offers complete analysis across various regions across the world. The Oncology Companion Diagnostics market is distributed into various regions such as North America, Europe, Asia Pacific, Latin America and Middle East and Africa. The global leading market share as per the region is evaluated after considering Oncology Companion Diagnostics market revenue, sales, shares, recent developments, innovations and growth rates. This section of regional analysis provides widespread evaluation of the industry from various countries and regions.

North America Oncology Companion Diagnostics Market Value and Forecast
  • US
  • Canada
Europe Oncology Companion Diagnostics Market Value and Forecast
  • UK
  • Germany
  • France
  •  Rest of Europe
Asia Pacific Oncology Companion Diagnostics Market Value and Forecast
  • China
  • Japan
  • India
  • Rest of Asia Pacific
Latin America Oncology Companion Diagnostics Market Value and Forecast
  • Mexico
  • Brazil
  • Rest of Latin America
Middle East and Africa Oncology Companion Diagnostics Market Value and Forecast
  • GCC Countries
  • South Africa
  • Rest of Middle East and Africa


Key highlights of the Oncology Companion Diagnostics market report:
  • The report provides key trends of the global Oncology Companion Diagnostics market
  • The report also covers consumer preferences and current industry growth
  • Key products or solutions offered by the main players in the Oncology Companion Diagnostics industry
  • The report covers all the recent developments of the Oncology Companion Diagnostics market and helps to provide current industry updates
  • The report covers a detailed look over the global Oncology Companion Diagnostics Industry and provides with significant actionable insights
  • The Oncology Companion Diagnostics market estimation from 2020-2028 and historical data for 2018 and 2019
  • The market study also provides data on changing market dynamics, market intelligence, current and future market trends
  • The report also analyses the microeconomic and macroeconomic factors that are affecting the global Oncology Companion Diagnostics market
  • In-depth analysis of the market’s competitive landscape and detailed information about the vendors
  • The report also offers key market drivers, restrains, trends and opportunities with present and future impact on the market
  • Detailed information about the major players or manufacturers of the global Oncology Companion Diagnostics market
  • Comprehensive analysis of the Oncology Companion Diagnostics market segments based on its types, applications and end-use industry
Key Analytical Areas:
The report aims to offer a complete solution to various businesses operating in the Oncology Companion Diagnostics market in making strategic decisions based on credible information and actionable insights. Thereby, the report covers various aspects of your requirements such as industry overview, market dynamics, regional analysis and competitive landscape. The report aims to provide insights to businesses in the Oncology Companion Diagnostics market for numerous purposes such as:

     1. Strategic Decision Making:
With the help of this report, key decision makers can quickly analyze and identify growth opportunities in terms of numerous segments across various geographical regions. Thereby, this report enables organizations to identify and make strategic investments in specific market segments in order to gain maximum return on investment.

      2.  Actionable Insights:
The report offers a deep dive into how companies are leveraging market conditions to make the most in the Oncology Companion Diagnostics market. Thereby, the report offers numerous actionable insights into the best practices and key success factors relevant in the Oncology Companion Diagnostics market. Using the insights included in the report, businesses can make quick decisions to achieve success in business operations.

      3. Competitive Snapshot:
In addition, to detailed information on the companies operating in the Oncology Companion Diagnostics market, the report also includes a competitive snapshot of all the companies covered in the report. Thereby, this offers a visual representation of how all the companies stand comparatively based on their competencies, geographic presence, market hold, years of operations, employee and financial strength, among others.

Manufacturers and Segments

  • Qiagen
  • Illumina
  • F. Hoffmann-La Roche Ltd.
  • Thermo Fisher Scientific, Inc
  • Agilent Technologies, Inc.
  • Arup Laboratories
  • Abbott
  • Myriad Genetics, Inc
  • Biomérieux SA
  • Invivoscribe
  • Instrument
  • Consumable
  • Software
  • Hospital
  • Pathology/Diagnostic Laboratory
  • Academic Medical Center

Have query on this report?

Make an Enquiry
1. Preface
     1.1. Report Scope and Description
     1.2. Research Methodology
          1.2.1. Phase I-Secondary Research
          1.2.2. Phase II-Primary Research
          1.2.3. Phase II-Expert Panel Review
          1.2.4. Assumptions
          1.2.5. Approach Adopted

2. Executive Summarysegment Form
     2.1. Global Oncology Companion Diagnostics Market Snapshot
          2.1.1. Global Oncology Companion Diagnostics Market By Product,2019
               2.1.1.1.Instrument
               2.1.1.2.Consumable
               2.1.1.3.Software
          2.1.2. Global Oncology Companion Diagnostics Market By End User,2019
               2.1.2.1.Hospital
               2.1.2.2.Pathology/Diagnostic Laboratory
               2.1.2.3.Academic Medical Center
          2.1.3. Global Oncology Companion Diagnostics Market By End-use,2019
          2.1.4. Global Oncology Companion Diagnostics Market By Geography,2019

3. Global Oncology Companion Diagnostics Market Dynamics
     3.1. Market Overview
     3.2. Market Inclination Insights Analysis
     3.3. Drivers
     3.4. Challenges
     3.5. Future Prospects
     3.6. Impact Analysis of Drivers and Challenges During the Forecast Period, (2020-2028)

4. Global Oncology Companion Diagnostics Market Size (US$), By Product, 2018 – 2028 
     4.1. Overview
          4.1.1. Market Share Analysis By Product, 2019 vs.2028
          4.1.2. Attractive Investment Proposition By Product, 2020
     4.2. Global Oncology Companion Diagnostics Market Size (US$), By Product, 2018 – 2028

5. Global Oncology Companion Diagnostics Market Size (US$), By End User, 2018 – 2028 
     5.1. Overview
          5.1.1. Market Share Analysis By End User, 2019 vs.2028
          5.1.2. Attractive Investment Proposition By End User, 2020
     5.2. Global Oncology Companion Diagnostics Market Size (US$), By End User, 2018 – 2028

6. Global Oncology Companion Diagnostics Market Size (US$), By End-use, 2018 – 2028 
     6.1. Overview
          6.1.1. Market Share Analysis By End-use, 2019 vs.2028
          6.1.2. Attractive Investment Proposition By End-use, 2020
     6.2. Global Oncology Companion Diagnostics Market Size (US$), By End-use, 2018 – 2028

7. Global Oncology Companion Diagnostics Market Size (US$), By Geography, 2018 – 2028
     7.1. Overview
          7.1.1. Market Share Analysis by Geography, 2019 vs. 2028
          7.1.2. Attractive Investment Proposition by Geography, 2020
     7.2. North America Oncology Companion Diagnostics Market Analysis, 2018 – 2028 
          7.2.1. North America Oncology Companion Diagnostics Market Size (US$), By Country, 2018 – 2028 
               7.2.1.1. U.S.
               7.2.1.2. Canada
          7.2.2. North America Oncology Companion Diagnostics Market Size (US$), By Product, 2018 – 2028
          7.2.3. North America Oncology Companion Diagnostics Market Size (US$), By End User, 2018 – 2028
          7.2.4. North America Oncology Companion Diagnostics Market Size (US$), By End-use, 2018 – 2028
     7.3. Europe Oncology Companion Diagnostics Market Analysis, 2018 – 2028 
          7.3.1.  Europe Oncology Companion Diagnostics Market Size (US$), By Country, 2018 – 2028 
               7.3.1.1. U.K.
               7.3.1.2. Germany
               7.3.1.3. France
               7.3.1.4. Rest of Europe
          7.3.2. Europe Oncology Companion Diagnostics Market Size (US$), By Product, 2018 – 2028
          7.3.3. Europe Oncology Companion Diagnostics Market Size (US$), By End User, 2018 – 2028
          7.3.4. Europe Oncology Companion Diagnostics Market Size (US$), By End-use, 2018 – 2028
     7.4. Asia Pacific Oncology Companion Diagnostics Market Analysis , 2018 – 2028
          7.4.1.  Asia Pacific Oncology Companion Diagnostics Market Size (US$), By Country, 2018 – 2028 
               7.4.1.1. China
               7.4.1.2. Japan
               7.4.1.3. India
               7.4.1.4. Rest of Asia Pacific
          7.4.2. Asia Pacific Oncology Companion Diagnostics Market Size (US$), By Product, 2018 – 2028
          7.4.3. Asia Pacific Oncology Companion Diagnostics Market Size (US$), By End User, 2018 – 2028
          7.4.4. Asia Pacific Oncology Companion Diagnostics Market Size (US$), By End-use, 2018 – 2028
     7.5. Latin America Oncology Companion Diagnostics Market Analysis, 2018 – 2028 
          7.5.1.  Latin America Oncology Companion Diagnostics Market Size (US$), By Country, 2018 – 2028 
               7.5.1.1. Brazil
               7.5.1.2. Mexico
               7.5.1.3. Rest of Latin America
          7.5.2. Latin America Oncology Companion Diagnostics Market Size (US$), By Product, 2018 – 2028
          7.5.3. Latin America Oncology Companion Diagnostics Market Size (US$), By End User, 2018 – 2028
          7.5.4. Latin America Oncology Companion Diagnostics Market Size (US$), By End-use, 2018 – 2028
     7.6. Middle East & Africa (MEA) Oncology Companion Diagnostics Market Analysis, 2018 – 2028 
          7.6.1.  MEA Oncology Companion Diagnostics Market Size (US$), By Region, 2018 – 2028 
               7.6.1.1. GCC Countries
               7.6.1.2. South Africa
               7.6.1.3. Rest of MEA
          7.6.2. MEA Oncology Companion Diagnostics Market Size (US$), By Product, 2018 – 2028
          7.6.3. MEA Oncology Companion Diagnostics Market Size (US$), By End User, 2018 – 2028
          7.6.4. MEA Oncology Companion Diagnostics Market Size (US$), By End-use, 2018 – 2028

8. Company Profiles
     8.1. Competitive Analysis 
     8.2. Market Positioning of Key Vendors 
     8.3. Key Strategies adopted by the Leading Players
     8.4. Key Oncology Companion Diagnostics Providers
        8.4.1 Qiagen
                8.4.1.1 Business Description
                8.4.1.2 Qiagen Geographic Operations
                8.4.1.3 Qiagen Financial Information
                8.4.1.4 Qiagen Product Positions/Portfolio
                8.4.1.5 Qiagen Key Developments
        8.4.2 Illumina
                8.4.2.1 Business Description
                8.4.2.2 Illumina Geographic Operations
                8.4.2.3 Illumina Financial Information
                8.4.2.4 Illumina Product Positions/Portfolio
                8.4.2.5 Illumina Key Developments
        8.4.3 F. Hoffmann-La Roche Ltd.
                8.4.3.1 Business Description
                8.4.3.2 F. Hoffmann-La Roche Ltd. Geographic Operations
                8.4.3.3 F. Hoffmann-La Roche Ltd. Financial Information
                8.4.3.4 F. Hoffmann-La Roche Ltd. Product Positions/Portfolio
                8.4.3.5 F. Hoffmann-La Roche Ltd. Key Developments
        8.4.4 Thermo Fisher Scientific, Inc
                8.4.4.1 Business Description
                8.4.4.2 Thermo Fisher Scientific, Inc Geographic Operations
                8.4.4.3 Thermo Fisher Scientific, Inc Financial Information
                8.4.4.4 Thermo Fisher Scientific, Inc Product Positions/Portfolio
                8.4.4.5 Thermo Fisher Scientific, Inc Key Developments
        8.4.5 Agilent Technologies, Inc.
                8.4.5.1 Business Description
                8.4.5.2 Agilent Technologies, Inc. Geographic Operations
                8.4.5.3 Agilent Technologies, Inc. Financial Information
                8.4.5.4 Agilent Technologies, Inc. Product Positions/Portfolio
                8.4.5.5 Agilent Technologies, Inc. Key Developments
        8.4.6 Arup Laboratories
                8.4.6.1 Business Description
                8.4.6.2 Arup Laboratories Geographic Operations
                8.4.6.3 Arup Laboratories Financial Information
                8.4.6.4 Arup Laboratories Product Positions/Portfolio
                8.4.6.5 Arup Laboratories Key Developments
        8.4.7 Abbott
                8.4.7.1 Business Description
                8.4.7.2 Abbott Geographic Operations
                8.4.7.3 Abbott Financial Information
                8.4.7.4 Abbott Product Positions/Portfolio
                8.4.7.5 Abbott Key Developments
        8.4.8 Myriad Genetics, Inc
                8.4.8.1 Business Description
                8.4.8.2 Myriad Genetics, Inc Geographic Operations
                8.4.8.3 Myriad Genetics, Inc Financial Information
                8.4.8.4 Myriad Genetics, Inc Product Positions/Portfolio
                8.4.8.5 Myriad Genetics, Inc Key Developments
        8.4.9 Biomérieux SA
                8.4.9.1 Business Description
                8.4.9.2 Biomérieux SA Geographic Operations
                8.4.9.3 Biomérieux SA Financial Information
                8.4.9.4 Biomérieux SA Product Positions/Portfolio
                8.4.9.5 Biomérieux SA Key Developments
        8.4.10 Invivoscribe
                8.4.10.1 Business Description
                8.4.10.2 Invivoscribe Geographic Operations
                8.4.10.3 Invivoscribe Financial Information
                8.4.10.4 Invivoscribe Product Positions/Portfolio
                8.4.10.5 Invivoscribe Key Developments

LIST OF TABLES

TABLE 1 Market Snapshot: Global Oncology Companion Diagnostics Market 
TABLE 2 Impact Indicators 
TABLE 3 Impact Analysis of Drivers and Restraints 
TABLE 4 North America Oncology Companion Diagnostics Market Revenue, By Product, 2018 – 2028 (US$ Mn) 
TABLE 5 North America Oncology Companion Diagnostics Market Revenue, By End User, 2018 – 2028 (US$ Mn) 
TABLE 6 North America Oncology Companion Diagnostics Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 7 Europe Oncology Companion Diagnostics Market Revenue, By Product, 2018 – 2028 (US$ Mn) 
TABLE 8 Europe Oncology Companion Diagnostics Market Revenue, By End User, 2018 – 2028 (US$ Mn) 
TABLE 9 Europe Oncology Companion Diagnostics Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 10 Asia Pacific Oncology Companion Diagnostics Market Revenue, By Product, 2018 – 2028 (US$ Mn) 
TABLE 11 Asia Pacific Oncology Companion Diagnostics Market Revenue, By End User, 2018 – 2028 (US$ Mn) 
TABLE 12 Asia Pacific Oncology Companion Diagnostics Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 13 Latin America Oncology Companion Diagnostics Market Revenue, By Product, 2018 – 2028 (US$ Mn) 
TABLE 14 Latin America Oncology Companion Diagnostics Market Revenue, By End User, 2018 – 2028 (US$ Mn) 
TABLE 15 Latin America Oncology Companion Diagnostics Market Revenue, By End-use, 2018 – 2028 (US$ Mn)
TABLE 16 MEA Oncology Companion Diagnostics Market Revenue, By Product, 2018 – 2028 (US$ Mn) 
TABLE 17 MEA Oncology Companion Diagnostics Market Revenue, By End User, 2018 – 2028 (US$ Mn) 
TABLE 18 MEA Oncology Companion Diagnostics Market Revenue, By End-use, 2018 – 2028 (US$ Mn)

LIST OF FIGURES

FIG. 1 Global Oncology Companion Diagnostics: Market Segmentation 
FIG. 2 Global Oncology Companion Diagnostics Market: Research Methodology 
FIG. 3 Top-Down and Bottom-up Approach 
FIG. 4 Global Oncology Companion Diagnostics Market, By Product, 2019 (US$ Mn) 
FIG. 5 Global Oncology Companion Diagnostics Market, By End User, 2019 (US$ Mn) 
FIG. 6 Global Oncology Companion Diagnostics Market, By End-use, 2019 (US$ Mn) 
FIG. 7 Global Oncology Companion Diagnostics Market, By Geography, 2019 (US$ Mn) 
FIG. 8 Global Oncology Companion Diagnostics Market Revenue and Growth, 2018 – 2028, (US$ Mn) (Y-o-Y %)
FIG. 9 Attractive Investment Proposition 
FIG. 10 Market Positioning of Key Oncology Companion Diagnostics Providers, 2019
FIG. 11 Global Oncology Companion Diagnostics Market Revenue Contribution, By Product, 2019 & 2028 (Value %) 
FIG. 12 Global Oncology Companion Diagnostics Market Revenue Contribution, By End User, 2019 & 2028 (Value %) 
FIG. 13 Global Oncology Companion Diagnostics Market Revenue Contribution, By End-use, 2019 & 2028 (Value %) 
FIG. 14 North America Oncology Companion Diagnostics Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 15 Europe Oncology Companion Diagnostics Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 16 Asia Pacific Oncology Companion Diagnostics Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 17 Latin America Oncology Companion Diagnostics Market Revenue, 2018 – 2028, (US$ Mn)
FIG. 18 MEA Oncology Companion Diagnostics Market Revenue, 2018 – 2028, (US$ Mn)

Key Takeaways:

1. Market value and estimate of the Oncology Companion Diagnostics market for the period from 2020 to 2028
2. Compounded annual growth rate (CAGR%) for individual segments in various regional markets for a period from 2020 to 2028
3. Value chain analysis
4. Market share study combined with competitive landscape of major players
5. Profiles of major market players covering overall business operations, geographic occurrence, product portfolio, financial status and news coverage 

List of Tables

TABLE  Market Snapshot: Global Oncology Companion Diagnostics Market
TABLE  Impact Pointers
TABLE  Impact Analysis of Drivers and Restraints
TABLE  North America Oncology Companion Diagnostics Market Value, By Segment1, 2018 – 2028
TABLE  North America Oncology Companion Diagnostics Market Value, By Segment2, 2018 – 2028
TABLE  North America Oncology Companion Diagnostics Market Value, By Country, 2018 – 2028
TABLE  Europe Oncology Companion Diagnostics Market Value, By Segment1, 2018 – 2028
TABLE  Europe Oncology Companion Diagnostics Market Value, By Segment2, 2018 – 2028
TABLE  Europe Oncology Companion Diagnostics Market Value, By Country, 2018 – 2028
TABLE  Asia Pacific Oncology Companion Diagnostics Market Value, By Segment1, 2018 – 2028
TABLE  Asia Pacific Oncology Companion Diagnostics Market Value, By Segment2, 2018 – 2028
TABLE  Asia Pacific Oncology Companion Diagnostics Market Value, By Country, 2018 – 2028
TABLE  Latin America Oncology Companion Diagnostics Market Value, By Segment1, 2018 – 2028
TABLE  Latin America Oncology Companion Diagnostics Market Value, By Segment2, 2018 – 2028
TABLE  Latin America Oncology Companion Diagnostics Market Value, By Country, 2018 – 2028
TABLE  MEA Oncology Companion Diagnostics Market Value, By Segment1, 2018 – 2028
TABLE  MEA Oncology Companion Diagnostics Market Value, By Segment2, 2018 – 2028
TABLE  MEA Oncology Companion Diagnostics Market Value, By Country, 2018 – 2028
TABLE  Qiagen: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Illumina: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  F. Hoffmann-La Roche Ltd.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Thermo Fisher Scientific, Inc: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Agilent Technologies, Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Arup Laboratories: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Abbott: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Myriad Genetics, Inc: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Biomérieux SA: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Invivoscribe: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
 

List of Figures

FIG.  Global Oncology Companion Diagnostics Market: Research Methodology
FIG.  Top-Down and Bottom Up Approach
FIG.  Global Oncology Companion Diagnostics Market, By Segment1, 2019 (US$ Mn)
FIG.  Global Oncology Companion Diagnostics Market, By Segment2, 2019 (US$ Mn)
FIG.  Global Oncology Companion Diagnostics Market, By Geography, 2019 (US$ Mn)
FIG.  Global Oncology Companion Diagnostics Market Value and Growth, 2018 – 2028, (US$ Mn) (Y-o-Y %)
FIG.  Attractive Investment Proposition
FIG.  Market Positioning of Key Oncology Companion Diagnostics Providers, 2016
FIG.  Global Oncology Companion Diagnostics Market Value Share, By Segment1, 2019 & 2028 (% Value)
FIG.  Global Consumable Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Software Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Oncology Companion Diagnostics Market Value Share, By Segment2, 2019 & 2028 (% Value)
FIG.  Global Pathology/Diagnostic Laboratory Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Academic Medical Center Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Market Value, 2018 – 2028, (US$ Mn)
FIG.  U.S. Oncology Companion Diagnostics Market Value, 2018 – 2028, (US$ Mn)
FIG.  Canada Oncology Companion Diagnostics Market Value, 2018 – 2028, (US$ Mn)
FIG.  UK Oncology Companion Diagnostics Market Value, 2018 – 2028, (US$ Mn)
FIG.  Germany Oncology Companion Diagnostics Market Value, 2018 – 2028, (US$ Mn)
FIG.  France Oncology Companion Diagnostics Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Europe Oncology Companion Diagnostics Market Value, 2018 – 2028, (US$ Mn)
FIG.  China Oncology Companion Diagnostics Market Value, 2018 – 2028, (US$ Mn)
FIG.  Japan Oncology Companion Diagnostics Market Value, 2018 – 2028, (US$ Mn)
FIG.  India Oncology Companion Diagnostics Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Asia Pacific Oncology Companion Diagnostics Market Value, 2018 – 2028, (US$ Mn)
FIG.  Mexico Oncology Companion Diagnostics Market Value, 2018 – 2028, (US$ Mn)
FIG.  Brazil Oncology Companion Diagnostics Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Latin America Oncology Companion Diagnostics Market Value, 2018 – 2028, (US$ Mn)
FIG.  GCC Countries Oncology Companion Diagnostics Market Value, 2018 – 2028, (US$ Mn)
FIG.  South Africa Oncology Companion Diagnostics Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of MEA Oncology Companion Diagnostics Market Value, 2018 – 2028, (US$ Mn)